Abstract PR014: Preliminary safety and anti-tumor activity of RMC-6291, a first-in-class, tri-complex KRASG12C(ON) inhibitor, in patients with or without prior KRASG12C(OFF) inhibitor treatmentPasi A. Jänne, Melissa L. Johnson, Frédéric Bigot et al.|Molecular Cancer Therapeutics|2023Cited by 60
Preliminary results of a phase II study of alrizomadlin (APG-115), a novel, small-molecule MDM2 inhibitor, in combination with pembrolizumab in patients (pts) with unresectable or metastatic melanoma or advanced solid tumors that have failed immuno-oncologic (I-O) drugs.Anthony W. Tolcher, Yifan Zhai, Alexander I. Spira et al.|Journal of Clinical Oncology|2021Cited by 23
140P Preliminary results from PROPEL: A phase I/II study of bempegaldesleukin (BEMPEG: NKTR-214) plus pembrolizumab (PEMBRO) with or without chemotherapy in patients with metastatic NSCLCEnriqueta Felip, Apar Kishor Ganti, David R. Spigel et al.|Annals of Oncology|2021Cited by 1
Brentuximab Vedotin in Frontline Therapy of Hodgkin Lymphoma in Patients with Significant Comorbidities Ineligible for Standard Chemotherapy (SGN35-015 Part E)Christopher A. Yasenchak, J. Thaddeus Beck, Shweta Jain et al.|Blood|2023Cited by 1